Cargando…

Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma

Rhabdomyosarcoma (RMS) is a family of soft tissue cancers that are related to the skeletal muscle lineage and predominantly occur in children and young adults. A specific chromosomal translocation t(2;13)(q35;q14) that gives rise to the chimeric oncogenic transcription factor PAX3-FOXO1 has been ide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Thanh Hung, Barr, Frederic G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278278/ https://www.ncbi.nlm.nih.gov/pubmed/30373318 http://dx.doi.org/10.3390/molecules23112798

Ejemplares similares

Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma
por: AHN, EUN HYUN, et al.
Publicado: (2013)

Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements
por: Vicente-García, Cristina, et al.
Publicado: (2017)

The PAX3-FOXO1 Fusion Protein Present in Rhabdomyosarcoma Interferes with Normal FOXO Activity and the TGF-β Pathway
por: Schmitt-Ney, Michel, et al.
Publicado: (2015)

FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
por: Milewski, David, et al.
Publicado: (2021)

Alveolar rhabdomyosarcoma – The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis
por: Marshall, Amy D, et al.
Publicado: (2012)

Negative correlation of single-cell PAX3:FOXO1 expression with tumorigenicity in rhabdomyosarcoma
por: Regina, Carla, et al.
Publicado: (2021)

PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors
por: Searcy, Madeline B., et al.
Publicado: (2023)

Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs
por: Manceau, Line, et al.
Publicado: (2022)

MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells
por: Cassandri, Matteo, et al.
Publicado: (2021)

PPP2R1A regulated by PAX3/FOXO1 fusion contributes to the acquisition of aggressive behavior in PAX3/FOXO1-positive alveolar rhabdomyosarcoma
por: Akaike, Keisuke, et al.
Publicado: (2018)

Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity
por: Nakazawa, Kay, et al.
Publicado: (2023)

JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells
por: Walters, Zoë S, et al.
Publicado: (2013)

Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options
por: Brown, Robert E., et al.
Publicado: (2016)

PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis
por: Kendall, Genevieve C, et al.
Publicado: (2018)

Synthetic MIR143-3p Suppresses Cell Growth in Rhabdomyosarcoma Cells by Interrupting RAS Pathways Including PAX3–FOXO1
por: Sugito, Nobuhiko, et al.
Publicado: (2020)

Cyclin-Dependent Kinase 4 Phosphorylates and Positively Regulates PAX3-FOXO1 in Human Alveolar Rhabdomyosarcoma Cells
por: Liu, Lingling, et al.
Publicado: (2013)

Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options
por: Loupe, J M, et al.
Publicado: (2015)

OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas
por: Kaleta, Magdalena, et al.
Publicado: (2019)

Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells
por: Yoshida, Hideki, et al.
Publicado: (2020)

The PAX-FOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition
por: Gonzalez Curto, Gloria, et al.
Publicado: (2020)

Modeling of the Human Alveolar Rhabdomyosarcoma Pax3-Foxo1 Chromosome Translocation in Mouse Myoblasts Using CRISPR-Cas9 Nuclease
por: Lagutina, Irina V., et al.
Publicado: (2015)

Identify potential driver genes for PAX-FOXO1 fusion-negative rhabdomyosarcoma through frequent gene co-expression network mining
por: Zhan, Xiaohui, et al.
Publicado: (2023)

Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma
por: Fulda, Simone
Publicado: (2012)

Progression and Differentiation of Alveolar Rhabdomyosarcoma Is Regulated by PAX7 Transcription Factor—Significance of Tumor Subclones
por: Skrzypek, Klaudia, et al.
Publicado: (2021)

PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma
por: Hanna, Jason A., et al.
Publicado: (2018)

Carnitine palmitoyltransferase 1A (CPT1A): a transcriptional target of PAX3-FKHR and mediates PAX3-FKHR–dependent motility in alveolar rhabdomyosarcoma cells
por: Liu, Lingling, et al.
Publicado: (2012)

Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma
por: Kanayama, Takuyo, et al.
Publicado: (2021)

ACTA1 is inhibited by PAX3-FOXO1 through RhoA-MKL1-SRF signaling pathway and impairs cell proliferation, migration and tumor growth in Alveolar Rhabdomyosarcoma
por: Hu, Qiande, et al.
Publicado: (2021)

FOXO Signaling Pathways as Therapeutic Targets in Cancer
por: Farhan, Mohd, et al.
Publicado: (2017)

Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma
por: Tenente, Inês M, et al.
Publicado: (2017)

Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma
por: Dehner, Carina A., et al.
Publicado: (2021)

PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma
por: Hanna, J A, et al.
Publicado: (2016)

KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1‐driven and independent disease‐promoting gene expression in fusion‐positive Rhabdomyosarcoma
por: Sobral, Lays M., et al.
Publicado: (2020)

PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells
por: Tiffin, N, et al.
Publicado: (2003)

Targeting the Hedgehog Pathway in Rhabdomyosarcoma
por: Zarzosa, Patricia, et al.
Publicado: (2023)

Too much AKT turns PAX3-FKHR dead: A prospect of novel therapeutic strategy for alveolar rhabdomyosarcoma
por: Jothi, Mathivanan, et al.
Publicado: (2012)

Therapeutic targeting of ATR in alveolar rhabdomyosarcoma
por: Dorado García, Heathcliff, et al.
Publicado: (2022)

PAX3 is a novel tumor suppressor by regulating the activities of major signaling pathways and transcription factor FOXO3a in thyroid cancer
por: Liu, Wei, et al.
Publicado: (2016)

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
por: Odeniyide, Patience, et al.
Publicado: (2022)

Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls
por: Hinson, Ashley R. P., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jq5soqgi3t2bp1re7gb9c4d406